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Abstract
Objectives: To describe fracture rates, back pain, and health-related quality of life (HRQoL) in
postmenopausal women with osteoporosis and prior bisphosphonate therapy, treated with teriparatide
for up to 18 months and followed up for a further 18 months.
Design: Prospective, multinational, and observational study.
Methods: Data on prior bisphosphonate use, clinical fractures, back painvisual analog scale (VAS), and
HRQoL (EQ-5D) were collected over 36 months. Fracture data were summarized in 6-month intervals
and analyzed using logistic regression with repeated measures. Changes from baseline in back pain
VAS and EQ-VAS were analyzed using a repeated measures model.
Results: Of the 1581 enrolled patients with follow-up data, 1161 (73.4%) had a history of prior
bisphosphonate use (median duration: 36 months). Of them, 169 (14.6%) sustained R1 fracture
during 36-month follow-up. Adjusted odds of fracture were signiﬁcantly decreased at each 6-month
interval compared with the ﬁrst 6 months of teriparatide treatment: 37% decrease in the 12 to !18
months period during teriparatide treatment (PZ0.03) and a 76% decrease in the 12- to 18-month
period after teriparatide was discontinued (P!0.001). Signiﬁcant reductions in back pain and
improvement in HRQoL were observed.
Conclusions: Postmenopausal women with severe osteoporosis previously treated with bisphosphonates
had a signiﬁcant reduction in the incidence of fractures compared with the ﬁrst 6 months of therapy, a
reduction in back pain and an improvement in HRQoL during up to 18 months of teriparatide
treatment. These outcomes were still evident for at least 18 months after teriparatide was
discontinued. The results should be interpreted in the context of an uncontrolled, observational
study in a routine clinical setting.
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Introduction
Postmenopausal women with osteoporosis have
increased risk of fractures and associated complications,
such as chronic back pain, eventually leading to
reduced health-related quality of life (HRQoL) (1–3).
Osteoporosis treatment aims to reduce fracture risk and
its associated burden. Antiresorptives, especially bispho-
sphonates, are routinely used as ﬁrst-line treatment for
postmenopausal osteoporosis (4–6).
Teriparatide recombinant DNA origin human
parathyroid hormone (1–34), PTH 1-34 is a bone
anabolic agent that reduces the risk of vertebral and
non-vertebral fractures in postmenopausal women
with osteoporosis (7). It also reduces the risk of
vertebral fractures in men with primary osteoporosis
(8), and in women and men with glucocorticoid-
induced osteoporosis (9). Teriparatide is typically used
as a second-line treatment for patients with severe
osteoporosis who are at high risk of fracture. It is also
an alternative treatment for patients who have contra-
indications or are intolerant of other osteoporosis
agents, or who sustained new fractures while on other
osteoporosis medications. Thus, in clinical practice, the
majority of patients receiving teriparatide have pre-
viously received at least one of different types of
bisphosphonates. However, published data on the effect
of sequential treatment regimens are scarce.
Some clinical trials have shown that previous
exposure to bisphosphonates can delay the increase in
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tide treatment (10–13). However, no previous clinical
trials or observational studies involving postmenopau-
sal women with osteoporosis have speciﬁcally examined
the effectiveness of teriparatide treatment on the
fracture risk of patients previously treated with
bisphosphonates.
The European Forsteo Observational Study (EFOS)
was a 36 month, prospective, observational study
initiated soon after the European approval of teripara-
tide for the treatment of postmenopausal women with
established osteoporosis at high risk for fracture. EFOS
was designed to collect data from an outpatient setting
and to evaluate fracture outcomes, back pain, and
HRQoL in postmenopausal women with severe osteo-
porosis treated with teriparatide for up to 18 months,
followed by a post-teriparatide treatment period of a
further 18 months (14). The women who participated
in EFOS were at very high riskoffracture as indicated by
their age, low BMD values, number of prior osteoporotic
fractures, numerous comorbidities, and risk factors for
low bone mass and falls (14).
Although randomized clinical trials (RCTs) are
considered the gold standard for investigating drug
effects, their design, in general, limits the capacity to
provide answers to questions about unselected ‘real-life’
patient populations and issues found only in clinical
practice (15). RCTs have rigorous entry criteria and a
fairly homogenous patient population, which may differ
from patients in real-life practice who often have
comorbidities and use concomitant medications that
commonly exclude them from controlled clinical trials
(16). Moreover, in real-life clinical practice, most
patients receiving teriparatide have been pre-treated
with other osteoporosis therapies.
There is no published information about fracture
risk and QoL after anabolic teriparatide treatment in
patients pre-treated with bisphosphonates. Hence,
the aim of this pre-deﬁned analysis is to describe
clinical fracture outcomes, back pain, and HRQoL in
the EFOS subgroup of postmenopausal women with
osteoporosis previously treated with bisphosphonates.
Another important feature of this study is that we
evaluated outcomes in the context of patients receiving
sequential therapy (as is usual in clinical practice).
We describe these outcomes both during treatment
with teriparatide for up to 18 months and in the
subsequent 18-month follow-up period after teri-
paratide was discontinued when most patients were
receiving other osteoporosis medications to investi-
gate a potential sustained effect after teriparatide
treatment was stopped. The changes in clinical
vertebral and non-vertebral fracture risk, back pain,
and HRQoL during the up to 18-month teriparatide
treatment period and the 18-month follow-up period
for the total study cohort have been reported
previously (17, 18).
Materials and methods
Study design and patients
EFOS was a multicenter, prospective, observational
study conducted in eight European countries (Austria,
Denmark, France, Germany, Greece, Ireland, The
Netherlands, and Sweden). The study design and
characteristics of the patient population have been
described in detail elsewhere (14). Brieﬂy, the study
enrolled 1649 postmenopausal women with a diagnosis
of established osteoporosis who, at the discretion of their
physician, were about to initiate teriparatide treatment.
Patients were followed for the duration of their
teriparatide treatment (20 mg once daily by s.c.
injection), which could be discontinued at any time,
and were asked to return for two additional visits after
discontinuing teriparatide, irrespective of when they
stopped teriparatide administration. Patients were not
included in the study if they were currently being
treated with an investigational drug or procedure, or
had any contraindications as described in the teripara-
tide label (19). The observational design meant there
were no further restrictions for the selection of
patients and all patient care provided was according
to the clinical judgment and usual practice of the
participating physicians.
Women provided written informed consent before
enrollment and were able to withdraw without
consequence at any time. The study was approved by
local ethics committees or review boards, depending on
local requirements, and was conducted in accordance
with the ethics standards of the Declaration of
Helsinki. The study was conducted from April 2004
(ﬁrst patient enrolled) until February 2009 (last patient
completed).
Data collection and outcomes
Patient demographic characteristics, risk factors for
osteoporosis and falls, disease status as well as the
number and type of prior and current medications for
the treatment of osteoporosis was recorded (14).
Information on compliance with previous treatments,
including prior bisphosphonate therapy, was not
collected. Participants attended visits at baseline (when
teriparatidewasinitiated)andthenatw3,6,12,and18
months after teriparatide initiation, and at 6 and 18
months after discontinuing teriparatide treatment.
Diagnosis of osteoporosis was documented by medical
history and, where appropriate, conﬁrmed by dual
X-ray absorptiometry. Incident clinical vertebral and
non-vertebral fragility fractures during the observa-
tional period were diagnosed and conﬁrmed by reviewof
the original X-rays and/or the radiology or surgical
reports at the investigational site. Different from typical
clinical trial procedures, there was no scheduled
vertebral radiograph to capture potential asymptomatic
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Therefore, vertebral fractures were only diagnosed if
these were clinical fractures, i.e. after a patient became
symptomatic with signs and/or symptoms suggestive of
a new vertebral fracture (20), which was then
conﬁrmed by radiography.
Back pain was self-assessed by patients at each study
visit using two different tools: i) a 100 mm visual analog
scale (VAS), ranging from 0Zno back pain to 100Z
worst possible back pain and ii) a back pain ques-
tionnaire that captured the frequency and severity of
back pain as well as its impact on patient activity in the
previous month (17).
HRQoL was measured at each visit using the
European Quality of Life Questionnaire (EQ-5D; for-
merly EuroQol) (21). Patients classiﬁed their own health
status according to ﬁve dimensions of health (mobility,
self-care, usual activities, pain/discomfort, and anxie-
ty/depression) each of which was scored on a three-
point scale (no problems, some problems, or extreme
problems). Patients also completed another VAS (EQ-
VAS), which assessed their perceived overall health
status on a scale from 0 (worst imaginable health state)
to 100 (best imaginable health state). The health state
value (HSV) was calculated from the ﬁve EQ-5D
dimensions using the UK scoring algorithm, to allow
for comparisons across countries (22).
Statistical analysis
For data analyses, the total study cohort included all
patients with a baseline visit and at least one follow-up
visit. In addition, the post-teriparatide cohort included
those patients who discontinued teriparatide treatment
at any time between baseline and 18 months and had at
least one post-teriparatide follow-up visit. Patients were
categorized as either prior bisphosphonate users or no
prior bisphosphonate users. Prior bisphosphonate users
were deﬁned as those taking bisphosphonates any time
before the baseline visit, or currently taking bispho-
sphonates at the baseline visit. Patients in the no prior
bisphosphonate use group could have prior use of any
other type of antiresorptive medications or be treat-
ment-naı ¨ve.
Descriptive statistics, such as frequencies, percen-
tages, means, median, S.D., and ranges, were used to
describe the characteristics of the groups with and
without prior bisphosphonate use. These were
compared by c
2 or Fisher’s exact tests for categorical
variables and the Kruskal–Wallis or t-test for continu-
ous variables.
The number of fractures occurring in prior bisphos-
phonate users was summarized in 6-month intervals.
A logistic regression with repeated measures was used
to assess the change in number of patients with one or
more fractures over time (23, 24), giving an analysis of
the odds of one or more fractures. Patients were
included in the model at all observed intervals,
regardless of whether or not they had fractured during
a previous interval. The repeated observations of each
patient were assumed to be related but no further
assumptions were made about the relationship. Unad-
justed and adjusted analyses (includingageand fracture
in the last 12 months before starting teriparatide) were
performed. The risk of fracture, calculated as the ratio of
fractured vs non-fractured patients (odds), was reported
for the ﬁrst 6 months of treatment (0 to !6 months)
and for each subsequent 6-month interval. Odds ratio
(ORs) and 95% conﬁdence intervals (CIs) were derived
to compare the risk at each of the subsequent 6-month
intervals with the ﬁrst 6 months of treatment (0 to !6
months). Fracture modeling was repeated for all
vertebral, all non-vertebral, and main non-vertebral
(forearm/wrist, hip, humerus, leg, and sternum/ribs)
fractures.
Back pain and HRQoL were summarized over the
teriparatide treatment period and after teriparatide
discontinuation. The Cochran–Mantel–Haenszel test
was used for between-group comparisons of categorical
variables and the Kruskal–Wallis or t-test for between-
group comparisons of continuous variables.
Changes in back pain VAS from baseline were
analyzed by a mixed model of repeated measures
(MMRM), using prior bisphosphonate use subgroup,
months and their interaction as ﬁxed effects and
adjusting for back pain VAS at baseline, number of
previous fractures, age, diagnosis of rheumatoid
arthritis, duration of prior bisphosphonate therapy,
and a history of fracture in the 12 months before
entering the study. The percentage of patients reporting
an improvement or worsening in the severity of back
pain, frequencyof back pain, limitation of activities, and
number of days in bed due to back pain was analyzed
by the sign test.
A similar MMRM was used to assess the change from
baseline in EQ-VAS, including its baseline value. The
percentage of patients reporting an improvement or
worsening from baseline in each of the ﬁve EQ-5D
domains was analyzed by the sign test. Changes from
baseline in EQ-5D HSV were assessed by the Wilcoxon
sign-rank test because this parameter has a nonpara-
metric distribution.
Results
Patients and baseline characteristics
Of the 1649 postmenopausal women with osteoporosis
enrolled in EFOS, 1581 had a baseline visit and at least
one post-baseline visit comprising the total studycohort
(Fig. 1). Of these patients, 1161 (73.4%) had a historyof
prior or current bisphosphonate use at the baseline
visit. Patient disposition throughout the observation for
the subgroups with and without prior bisphosphonate
use is shown in Fig. 1.
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of the patients are summarized in Table 1. The type and
duration of prior bisphosphonate treatment are given in
Table 2. In the subgroup with prior bisphosphonate use,
91 (10.3%) were still taking a bisphosphonate at the
baseline visit, and 19 (1.7%), 21 (2.0%), and 24 (2.5%)
patients reported taking a bisphosphonate at the 3-, 6-,
and 12-month visits respectively. Prior bisphosphonate
user patients were signiﬁcantly older and had a lower
BMI than the group of patients who were bispho-
sphonate-naı ¨ve. The prior bisphosphonate users had a
higher mean lumbar spine BMD T-score at baseline, but
more frequently reported a history of previous fracture,
surgical menopause, sight problems, glucocorticoid,
anticonvulsant, and benzodiazepine use than the
bisphosphonate-naı ¨ve group. Prior bisphosphonate
users also reported a larger number of prevalent
fractures (Table 1).
Teriparatide treatment and osteoporosis
medication taken during and after
teriparatide
The median duration of teriparatide treatment was
similar in the two groups: 541 days (Q1, Q3: 451, 553)
for the prior bisphosphonate group and 541 days (Q1,
Q3: 375, 551) for the group without prior bisphos-
phonate use. Persistence with teriparatide treatment
was high and similar for the groups with and without
prior bisphosphonate use (see Supplementary Figure 1,
see section on supplementary data given at the end of
this article).
In the subgroup of prior bisphosphonate users,
calcium was taken at baseline or any time during the
study by 1077 (92.9%) patients and vitamin D was
taken by 1067 (92.1%) patients. For the subgroup
without prior bisphosphonate use, calcium and vitamin
D were taken by 358 (85.2%) and 355 (84.5%) patients
respectively.
Of the prior bisphosphonate users with data on
osteoporosis medication taken after teriparatide was
discontinued (nZ639), 454 (71.0%) took an anti-
resorptive, mainly a bisphosphonate (nZ427, 66.8%).
Likewise, for the non-prior bisphosphonate users
(nZ268), 187 (69.8%) took an antiresorptive, mainly
a bisphosphonate (nZ147, 54.9%) after discontinu-
ation of teriparatide.
Fracture outcomes
The incidence of clinical fractures in prior bisphos-
phonate users during the observation period is
summarized in Table 3. Of the 1161 women in the
prior bisphosphonate group, 169 (14.6%) sustained a
total of 212 clinical fractures during the 36-month
follow-up. Of the 169 prior bisphosphonate users with
incident fractures, 136 sustained a single fracture
during the 36-month follow-up period and 33
sustained two or more fractures. Of the total 212
fractures, 70 (33.0%) were clinical vertebral fractures
and 142 (67.0%) were non-vertebral fractures; 106
(50.0%) of all fractures were main non-vertebral
fractures at the forearm/wrist (nZ34), hip (nZ22),
humerus (nZ19), leg (nZ18), and sternum/ribs
(nZ13). Table 3 shows that there was a signiﬁcant
risk reduction of clinical fractures at each subsequent
6-month interval compared with the ﬁrst 6 months of
teriparatide treatment (0 to !6 months): there was
a 37% decrease in the odds of fracture in the 12 to
!18 months period during teriparatide treatment,
and a 76% decrease in the 12 to !18 months period
after teriparatide was discontinued (i.e. from 30 to
!36 months follow-up). Prior bisphosphonate users
who had a fracture in the 12 months before baseline
were more likely to fracture during the study than
those without a fracture in the 12 months before
baseline (adjusted OR 1.39; 95% CI: 1.06–1.84;
PZ0.019).
Figure 2 presents the risk of fracture (adjusted odds
with 95% CIs) by fracture type for each 6-month
interval in patients who were treated with bispho-
sphonates before teriparatide. For vertebral fractures,
there was a signiﬁcant risk reduction at 12 to !18
months of teriparatide treatment and during the post-
teriparatide period, compared with the ﬁrst 6 months
of teriparatide treatment. The risk of having a non-
vertebral fracture was signiﬁcantly lower during the
24 to !30 months interval, resulting in an OR of 0.41
(95% CI: 0.21–0.82) and the 30 to !36 months
interval (OR 0.37; 95% CI: 0.18–0.76), compared
with the ﬁrst 6 months of teriparatide treatment.
Similar results were seen for the main non-vertebral
fractures (Fig. 2).
Postmenopausal women enrolled
(n=1649)
Total study cohort
(n=1581)
No prior BP use
Baseline (n=420)
Prior BP use
Baseline (n=1161)
No more data (n=67)
No follow-up visit (n=68)
Teriparatide
treatment for
up to 18
months
Teriparatide
discontinued
No more data (n=53)
No more data (n=62)
No more data (n=122)
No more data (n=148)
No more data (n=15)
No more data (n=19)
No more data (n=22)
No more data (n=34)
No more data (n=33
3 months (n=388)
Missed visit (n=32)
3 months (n=1095)
Missed visit (n=66)
6 months (n=1042)
Missed visit (n=52)
6 months (n=387)
Missed visit (n=18)
12 months (n=972)
Missed visit (n=69)
12 months (n=368)
Missed visit (n=18)
18 months (n=944)
Missed visit (n=35)
12 months (n=355)
Missed visit (n=9)
24 months (n=799)
Missed visit (n=58)
24 months (n=304)
Missed visit (n=26)
36 months (n=709)
Total study cohort: all patients with a baseline visit and at least one post-baseline visit
36 months (n=297)
Figure 1 Study ﬂow and disposition of patients in the prior
bisphosphonate (BP) use and no prior BP use groups in the total
study cohort.
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evidence offurther changein fracture risk during the 18
months after stopping teriparatide (see Supplementary
Table 1, see section on supplementary data given at the
end of this article).
In the group without prior bisphosphonate therapy
(nZ420), 39 (9.3%) patients sustained a total of 46
fractures. Of the 46 fractures, 17 (37%) were vertebral
and 29 (63%) were non-vertebral fractures, including
forearm/wrist (nZ7), sternum/ribs (nZ6), hip (nZ5),
leg (nZ3), and humerus (nZ2). The adjusted
regression model found no statistically signiﬁcant
reduction in the risk of clinical fractures during each
6-month interval compared with the ﬁrst 6 months of
teriparatide treatment (data not shown) probably
because of the low number of cases.
Back pain
There were statistically signiﬁcant reductions in the
adjusted mean change in back pain VAS from baseline
at each post-baseline visit in the groups with and
without prior bisphosphonate use (Fig. 3). The between-
group analyses revealed that the reduction in back pain
VAS score was signiﬁcantly higher in the group with no
prior bisphosphonate use at all post-baseline time points
(Fig. 3), although the absolute difference was !11 mm.
Results from the back pain questionnaire in prior
bisphosphonate users (see Supplementary Table 2, see
section on supplementary data given at the end of this
article) showed reductions in both the frequency and
severity of back pain and in the limitations of activities
because of back pain during teriparatide treatment.
Table 1 Demographics and other patient characteristics at baseline by prior bisphosphonate (BP) use. Data are
presented as mean (S.D.) unless stated otherwise.
Characteristic
Prior BP use
(nZ1161)
NopriorBPuse
a
(nZ420) P value
b
Demographics
Age (years) 71.2 (8.1) 70.2 (9.0) 0.038
Caucasian (%) 99.1 99.5 0.738
BMI (kg/m
2) 25.0 (4.3) 25.5 (4.3) 0.035
Menopausal status
Early menopause, !40 years of age (%) 8.4 10.4 0.253
Surgical menopause (%) 20.4 13.9 0.005
Risk factors
Nulliparous (%) 13.5 11.9 0.401
Current smoker (%) 13.2 12.4 0.675
Osteoporotic hip fracture in mother (%) 20.3 22.4 0.445
Lumbar spine BMD T-score K3.22 (1.22) K3.41 (0.96) 0.018
Total hip BMD T-score K2.59 (1.06) K2.71 (0.99) 0.087
Uses arms when standing up from chair (%) 60.8 70.2 0.001
Sight problems (%) 47.8 37.4 !0.001
O1 fall in the last year (%) 22.7 23.9 0.821
Concomitant medications 747 (65.0) 253 (60.5) 0.102
Antihypertensives (%) 36.6 39.0 0.377
Glucocorticoids (%)
c 16.1 11.2 0.017
Thyroid hormones (%) 13.3 13.4 0.967
Benzodiazepines (%) 13.2 8.6 0.013
Antidepressants (%) 10.9 8.4 0.147
Anticonvulsants (%) 2.3 0 !0.001
Comorbidities
Rheumatoid arthritis (%) 12.4 10.5 0.296
Chronic obstructive pulmonary disease (%) 9.2 7.4 0.254
Diabetes mellitus (%) 4.7 7.9 0.014
Parkinson disease and other movement disorders (%) 1.2 2.9 0.023
Prior fractures
Patients with prior fractures (%) 91.6 78.3 !0.001
Time since most recent fracture (years)
d 0.9 (0.2:2.6) 0.4 (0.1:1.7) !0.001
Number of previous fractures after age 40 3.2 (2.0) 2.1 (1.7) !0.001
At least one fracture in 12 months before study entry (%) 47.2 51.7 0.117
Baseline back pain and HRQoL
Back pain VAS 57.1 (26.4) 59.4 (27.3) 0.135
EQ-VAS 52.2 (20.8) 51.6 (25.1) 0.653
aOf these 420 patients, 292 (69.5%) reported having prior osteoporosis medication use, mostly antiresorptives (nZ217, 51.7%); 121
(28.8%) reported being treatment naive; data on other osteoporosis medication was missing/unknown for seven patients.
bP values for age and BMI are calculated by pooled t-test; other continuous variables are calculated by the Kruskal–Wallis test. P values for
discrete variables are calculated by c
2 test, with the exception of Caucasian, which uses Fisher’s exact test.
cIn addition, glucocorticoid use during the study was higher in prior BP group than in the no prior BP group: 20.0 vs 14.8%, respectively;
PZ0.018.
dMedian time from baseline (Q1:Q3).
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treatment was discontinued. At every post-baseline
visit, the change from baseline (i.e. percentage of
patients reporting an improvement) in frequency of
back pain, severity of back pain, limitations of activities,
and days in bed due to back pain was signiﬁcant (sign
test, P!0.001; Supplementary Table 2, see section on
supplementary data given at the end of this article).
Health-related quality of life
There were signiﬁcant increases in EQ-VAS (i.e.
improvement in HRQoL) from baseline in both the
prior and no prior bisphosphonate user groups at all
post-baseline visits (Fig. 4). The increase in EQ-VAS was
statistically signiﬁcantly higher in the no prior bisphos-
phonate user group from the 6-month visit onwards
(Fig. 4). Furthermore, there was less improvement in
HRQoL with each additional 5 mm in baseline EQ-VAS
(K2.94 mm; 95% CI: K3.11 to K2.77; P!0.001),
every additional 5 years of age (K1.05 mm; 95% CI:
K1.51 to K0.60; P!0.001), each additional fracture
(K0.68 mm; 95% CI: K1.08 to K0.27; PZ0.001),
and a diagnosis of rheumatoid arthritis (K4.15 mm;
95% CI: K1.83 to K6.47; P!0.001).
The percentage of prior bisphosphonate users report-
ing some/extreme problems for each of the ﬁve EQ-5D
domains (see Supplementary Table 3, see section on
supplementary data given at the end of this article)
shows signiﬁcant improvements from baseline
(P!0.001, sign test) in all ﬁve EQ-5D domains during
teriparatide treatment that were maintained after
teriparatide was discontinued. In the prior bispho-
sphonate user group, median (Q1, Q3) HSV increased
from 0.587 (0.088, 0.691) at baseline to 0.691 (0.587,
0.796) at 18 months and increased further to 0.725
(0.587, 0.848) at 36 months. The change in HSV from
baseline was signiﬁcant at each visit (Wilcoxon signed-
rank test; P!0.001).
Discussion
The EFOS is the ﬁrst observational study to report
effectiveness results in clinical fractures risk reduction,
back pain, and HRQoL in postmenopausal women with
severe osteoporosis in routine clinical practice both
during teriparatide treatment for up to 18 months and
in the subsequent 18-month post-teriparatide period.
The subgroup of patients described in the current pre-
deﬁned analysis had received bisphosphonate therapy
for a substantial period of time (median 36 months)
before starting treatment with teriparatide. These
patients represent the majority of patients being treated
with teriparatide in Europe, given the reimbursement
and treatment guidelines with this drug, and con-
stituted 73.4% of subjects initiating teriparatide. Similar
to what we observed in the total study cohort (18), the
subgroup of prior bisphosphonate users showed a
signiﬁcant reduction in the odds of clinical fractures
during teriparatide treatment, with no evidence of
further change after teriparatide was discontinued.
Fracture reduction in this observational study could
not be compared with a placebo or another osteoporosis
medication, but rather was compared with the ﬁrst 6
months of teriparatide treatment. Applying this
approach, there was a 34% decrease in the adjusted
odds of fracture in the period from 6 months up to 12
months during teriparatide treatment, and a similar
Table 3 Incident clinical fractures during teriparatide treatment (0 to !18 months) and after teriparatide discontinuation (18 to !36
months) in prior bisphosphonate users (total study cohort).
Time interval
(months)
n (data missing/
unknown)
No. of
fractures/10 000
pt-years
Total no.
of fractures
Patients with
R1 fracture
n (%)
a
Odds ratio
b,c
(95% CI) P
0t o!6 1161 (3) 1299 73 65 (5.6) – –
6t o!12 1077 (2) 926 48 41 (3.8) 0.66 (0.45, 0.98) 0.04
12 to !18 1000 (1) 783 38 36 (3.6) 0.63 (0.41, 0.96) 0.03
18 to !24 925 (1) 562 24 22 (2.4) 0.41 (0.25, 0.68) !0.001
24 to !30 786 (4) 467 17 15 (1.9) 0.33 (0.19, 0.59) !0.001
30 to !36 695 (0) 376 12 10 (1.4) 0.24 (0.13, 0.48) !0.001
Total 1161 (3) 212 169 (14.6)
aAs some patients experienced a fracture in more than one time interval, the total was not the sum of patients with a fracture in each interval.
bAdjusted model by age and a history of fracture in last 12 months before starting teriparatide.
cCompared with 0 to !6 months interval.
Table 2 Number (%) of patientswith prior bisphosphonate(BP) use
at the baseline visit and duration of prior use.
Number of
patients
a (% of
total study cohort,
nZ1581)
Duration of prior
therapy (months;
median (Q1:Q3))
Any prior BP use 1157 (73.6) 36 (16:66)
Alendronate 739 (47.0) 23 (8:44)
Risedronate 479 (30.5) 18 (8:34)
Etidronate 293 (18.6) 36 (18:57)
Other BP 155 (9.9) 26 (12:52)
aFour patients had incomplete BP data.
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www.eje-online.orgdecrease (37%) in the period from 12 months up to 18
months during teriparatide treatment. Interestingly,
after teriparatide was stopped, the reductions of the
odds of clinical fractures (range: 59–76%) were still
statistically signiﬁcant compared with the ﬁrst 6
months of treatment. Our results complement previous
follow-up data from the pivotal phase III trial (with
patients who had no prior bisphosphonate treatment),
where it was observed that those patients who received
teriparatide during the randomized, controlled phase
showed a 41% reduction in the hazard ratios of
vertebral fractures (25) and a 30% reduction in the
hazard ratios of non-vertebral fractures (26) at 18 and
30 months after stopping teriparatide, respectively,
compared with those patients who were originally
assigned to the placebo group. Similar to what was
observed during follow-up of the patients included in
the registration trials (25, 26), w70% of the subjects in
EFOS received another osteoporosis medication, mainly
a bisphosphonate, as part of the standard clinical care
after teriparatide was stopped. The results of our study
and those of the observational follow-up period of the
pivotal trial (25, 26), which found a sustained reduction
in fracture incidence after teriparatide was discontin-
ued, would support the use of an antiresorptive drug
after a full-course of teriparatide.
Because changes in bone microarchitecture, density
and strength take time to occur, it is highly likely that
fracture risk reduction does not occur immediately after
starting teriparatide therapy. For example, in the
placebo-controlled Fracture Prevention Trial, the
reduction in risk of non-vertebral fractures was not
seen until 9–12 months after starting teriparatide (7).
Hence, in the present observational study, our assump-
tion that the odds of fracture in the ﬁrst 6 months after
starting teriparatide reﬂects the baseline fracture risk in
the patient cohort appears to be justiﬁed. Therefore, we
compared the odds of fracture during each subsequent
6-month period with those in the initial 6-month period
after starting teriparatide therapy. This type of approach
has been used previously in an observational study of
the longitudinal change in fracture incidence during
bisphosphonate therapy (27). Our results are also
consistent with a recent analysis of data from the
pivotal Fracture Prevention Trial, where a progressive
decrease in the rate of non-vertebral fracture with
increasing duration of teriparatide therapy was
observed (28).
The ﬁndings of a sustained clinical fracture risk
reduction during and after teriparatide treatment in
patients with prior bisphosphonate use are of particular
clinical interest since the results of certain clinical
studies have created some controversy about whether
pre-treatment with potent antiresorptive agents that
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www.eje-online.orghave a long bone retention time (such as bispho-
sphonates) will inhibit the skeletal anabolic response to
PTH. Bisphosphonates selectively bind to the mineral
phase of bone matrix, markedly suppress bone acti-
vation frequency (29–32), have a (varying) long
retention time in bone (33), and suppress bone turnover
for many months after discontinuation (34). Therefore,
as a result of reduced bone turnover, we may expect a
delay in the increase of biochemical markers of bone
resorption and formation and of areal BMD after
starting teriparatide treatment in patients previously
treated with bisphosphonates, compared with either less
potent antiresorptives (e.g. raloxifene) or in treatment-
naı ¨ve patients (11). A slower increase in areal BMD
during the initial months of teriparatide treatment has
been demonstrated in the EUROFORS trial in those
patients pre-treated with antiresorptives (mainly
bisphosphonates), compared with treatment-naı ¨ve
patients (12). In spite of the delayed initial response to
teriparatide treatment, there were robust gains in BMD
between 18 and 24 months of teriparatide treatment,
especially in patients deﬁned as inadequate responders
to prior antiresorptive therapy (12). In the same study,
bone formation markers (which were reduced at
baseline in the antiresorptive pre-treated group
compared with treatment-naı ¨ve subjects) quickly
caught up after 1 month of teriparatide treatment,
and the levels of procollagen type I N-terminal
propeptide and bone-speciﬁc alkaline phosphatase
were no longer different among groups after 6 months
of treatment (35).
Several other clinical studies have shown that the
suppressive effects of a bisphosphonate pre-treatment
can be overcome during continued teriparatide treat-
ment, as assessed by quantitative histomorphometry
(36), by high-resolution computed tomography (HRCT)-
based structural analyses (37), by HRCT-based ﬁnite
element analyses (FEA) of vertebral trabecular bone
(38), and by CT-based analyses of biomechanical
properties of the femoral neck, which showed an
improvement in the moment of inertia and buckling
ratio after 24 months of teriparatide treatment (39).
These ﬁndings further support the recommendation
that there is no rationale for a washout period after
stopping a bisphosphonate therapy before initiating
teriparatide treatment (40, 41).
Previous research has indicated that the marked
suppression of bone turnover by bisphosphonates may
be associated with an increase in bone microcracks in
postmenopausal women with osteoporosis (42). While
it is unclear whether this microdamage accumulation
affects fracture risk, a recent study of iliac crest bone
biopsies has shown that teriparatide treatment can
reduce the microdamage accumulation in patients
previously treated with bisphosphonates and it might
be speculated that this may be associated with improved
bone structure and strength (43).
In a substudy of the OPTAMISE study using CT-based
FEA of the vertebral body, Chevalier et al. (44) found
that teriparatide treatment for 12 months resulted in a
greater increase in vertebral bone strength in patients
previously treated with risedronate than in those
previously treated with alendronate. However, because
these analyses were performed after only 12 months of
teriparatide treatment, we cannot drawanyconclusions
about whether there is a clinically relevant difference
between the two bisphosphonates.
We observed rapid and signiﬁcant improvements in
both back pain and HRQoL in the prior and no prior
bisphosphonate groups during teriparatide treatment,
and these beneﬁts were maintained 18 months after
teriparatide was discontinued. The smaller changes
from baseline in back pain VAS and EQ-VAS in the prior
bisphosphonate users may reﬂect a greater severity of
osteoporosis in this group of patients, as shown by their
baseline clinical risk factors. However, the baseline VAS
and EQ-VAS values were not different between groups.
Hence, another possible explanation for these
differences may be that the time since the most recent
clinical fracture was shorter in the bisphosphonate-
naı ¨ve group (0.4 vs 0.9 years in the prior bispho-
sphonate user group; i.e. w4.8 vs w10.8 months), and
the larger improvements in back pain and QoL may be
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during and after teriparatide treatment in patients with and without
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†P!0.05 vs prior BP users. Data presented are from MMRM
analysis using prior BP use subgroup, months and their interaction
as ﬁxed effectsand adjustingfor baselineEQ-VASscore, numberof
previous fractures, fracture in 12 months before study entry, age,
prior bisphosphonate duration, and diagnosis of rheumatoid
arthritis. For prior BP users, unadjusted mean (S.D.) EQ-VAS values
at baseline, 3, 6, 12, 18, 24, and 36 months and end of study
(L.O.C.F.), were 52.2 (20.8), 58.4 (19.2), 60.8 (19.5), 62.9 (21.0),
65.3 (20.9), 64.4 (21.9), 65.7 (22.2), and 62.3 (22.9) respectively.
The corresponding values for the no prior BP use group were 51.6
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20.0 (27.2) in the prior and no prior BP user groups respectively.
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resolution of back pain associated with a more recent
spine fracture. In any case, the absolute differences
between the two groups, albeit statistically signiﬁcant,
were small and in the range of clinically non-relevant
values (45). The back pain results observed in EFOS are
similar to previously reported values in the EUROFORS
trial (46).
Our study has several limitations. First, the infor-
mation on prior osteoporosis treatments was collected
retrospectively and was based on patient self-report. It
is, therefore, subject to recall bias. Moreover, although
we know that the median duration of prior bisphos-
phonate use was 36 months and that 10% of the prior
bisphosphonate user group were still taking a bisphos-
phonate at study enrollment, we do not know the lag
time between stopping previous therapy and starting
teriparatide. Secondly, because previous bisphospho-
nate therapy was not randomized, we cannot attribute
the observed differences to prior use of bisphosphonates.
Similarly, as there is no randomized comparison group,
the suggestive attribution of the observed changes in
endpoints to teriparatide is not controlled. Another
limitation is that we did not gather data on the use of
analgesics during the study, which may have affected
the back pain results. Finally, the maximum treatment
duration with teriparatide when the study was
conducted was 18 months in Europe, but the currently
approved duration is 24 months.
As the safety of teriparatide has already been
established and was not an objective of this observa-
tional study, adverse events were not collected as a part
of the study. Investigators were reminded to report any
signiﬁcant adverse events to the sponsor. All spon-
taneously reported adverse events for participants of the
study have been reported previously (17) and were
consistent with current prescribing information.
The strengths of our study include the large sample
size and the enrollment of a diverse range of subjects
without the strict inclusion and exclusion criteria used
in RCTs, reﬂecting normal clinical practice. Notably,
patients taking part in EFOS had comorbidities,
including rheumatoid arthritis, and received numerous
concomitant medications. Another advantage of EFOS
is that it examined patients with severe osteoporosis
receiving sequential therapies in the routine care
setting. Further work is needed to clarify the inﬂuence
of different sequential treatments on fracture risk
reduction.
In conclusion, we found that postmenopausal women
with severe osteoporosis previously treated with bisphos-
phonates who were prescribed teriparatide in a routine
setting had a signiﬁcant reduction in the incidence of
fractures that was accompanied by a reduction in back
pain and improvements in HRQoL during 18 months of
teriparatide treatment. These changes from baseline
were still evident 18 months after discontinuation of
teriparatide therapy when the majority of patients were
receiving other osteoporosis therapy. These ﬁndings
should be interpreted in the context of a non-controlled
observational study.
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